**Question:** The following is the indication of eptifibatide:

A. Acute myocardial infarction (AMI)
B. Unstable angina
C. Percutaneous coronary intervention (PCI)
D. Acute stroke

**Core Concept:**
Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist, which is a class of medications used to prevent blood clots formation and platelet aggregation. In the context of the question, the correct indication for eptifibatide is related to cardiovascular diseases, particularly those involving platelet activation and clot formation.

**Why the Correct Answer is Right:**
Eptifibatide is primarily used in the treatment of patients with acute coronary syndromes (ACS) like acute myocardial infarction (AMI) and unstable angina. In these conditions, the primary concern is excessive platelet aggregation and clot formation, which can lead to life-threatening complications. By blocking the glycoprotein IIb/IIIa receptors on platelets, eptifibatide effectively inhibits platelet activation and aggregation, thereby preventing clot formation and stabilizing the coronary plaque, reducing myocardial infarction and stroke risk.

**Why Each Wrong Option is Incorrect:**
A. Acute stroke (D): Eptifibatide is not indicated for treating stroke, which is caused by cerebral vascular occlusion and cerebral ischemia due to arterial occlusion or embolism. Eptifibatide's mechanism of action is not relevant to treating stroke.

B. Unstable angina (B): While unstable angina shares some similarities with ACS, eptifibatide is specifically designed to prevent clot formation and stabilize the coronary plaque, which is more pertinent to ACS than unstable angina. However, unstable angina still has a role in the management of ACS, especially when PCI is being performed.

C. Percutaneous coronary intervention (PCI) (C): PCI is an invasive procedure used to open blocked coronary arteries in patients with ACS. Eptifibatide is used alongside PCI to prevent platelet activation and clot formation, enhancing the success rate and safety of PCI procedures.

**Correct Answer:**
Eptifibatide is used in patients with acute coronary syndromes (ACS) like acute myocardial infarction (AMI) and unstable angina. The primary indication for eptifibatide is its ability to inhibit platelet aggregation and reduce myocardial infarction and stroke risk by stabilizing the coronary plaque. In patients undergoing percutaneous coronary intervention (PCI), eptifibatide is used as an adjunct to prevent clot formation and enhance PCI success.